SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the kidney and therefore lower blood sugar.[1] They act by inhibiting sodium/glucose cotransporter 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes.[2][3] As of 2014[update], several medications of this class had been approved or were under development.[4] In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.[5]
^Shubrook J, Baradar-Bokaie B, Adkins S (2015). "Empagliflozin in the treatment of type 2 diabetes: Evidence to date". Drug Design, Development and Therapy. 9: 5793–803. doi:10.2147/DDDT.S69926. PMC 4634822. PMID 26586935.
^Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. (2018). "Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis". European Journal of Preventive Cardiology. 25 (5): 495–502. doi:10.1177/2047487318755531. PMID 29372664. S2CID 3557967.
^Bonora BM, Avogaro A, Fadini GP (2020). "Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 13: 161–174. doi:10.2147/DMSO.S233538. PMC 6982447. PMID 32021362.
^Scheen AJ (2014). "Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus". Drugs. 75 (1): 33–59. doi:10.1007/s40265-014-0337-y. PMID 25488697. S2CID 9350259.
^Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD (2014). "Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin". Nutrition & Diabetes. 4 (11): e143. doi:10.1038/nutd.2014.40. PMC 4259905. PMID 25365416.
SGLT2inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional...
adverse event, it is thought to be more common if someone receiving an SGLT2inhibitor who is also receiving insulin has reduced or missed insulin doses....
absorbed from the gastrointestinal tract. SGLT2 inhibition: Inhibition of sodium-glucose transport protein 2 (SGLT2) decreases glucose reabsorption in the...
not recommended. Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works by increasing the amount of glucose lost in the urine. Canagliflozin...
in adults with type 2 diabetes. Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney...
steroids, or malignancy. Fournier gangrene is a rare side effect of SGLT2inhibitors (canagliflozin, dapagliflozin, and empagliflozin), which increase the...
surgery, the FDA has approved changes to the prescribing information for SGLT2inhibitor diabetes medicines to recommend they be stopped temporarily before...
they frequently develop low blood pressure. In patients with HFpEF, SGLT2inhibitors carry a class 2a recommendation according to the 2022 ACC/AHA/HFSA...
state of ketosis, especially several classes of diabetes medication. SGLT2inhibitor medications have been associated with cases of euglycemic ketoacidosis...
A phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a vasodilating drug that works by blocking the degradative action of cGMP-specific phosphodiesterase...
the Study of Diabetes recommend using a GLP-1 receptor agonist or SGLT2inhibitor as the first-line treatment in patients who have or are at high risk...
Additionally, SGLT2inhibitor medications ("gliflozins" or "flozins") produce glycosuria as their primary mechanism of action, by inhibiting sodium/glucose...
Research 12.2 (2015): 90–100. PMC. Web. 11 Nov. 2017 Story of Discovery: SGLT2Inhibitors: Harnessing the Kidneys to Help Treat Diabetes.” National Institute...
cotransporter 2 (SGLT2) inhibitor (gliflozin). These membrane proteins are on the cell surface and transfer glucose into the cells. SGLT2 is one subtype...
Trial of SGLT2 Antisense Drug". van Meer L, van Dongen M, Moerland M, de Kam M, Cohen A, Burggraaf J (February 2017). "Novel SGLT2inhibitor: first-in-man...
treatment of cats. Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It is taken by mouth. Velagliflozin is indicated to improve glycemic...
cotransporter 2. Additionally, SGLT2inhibitor medications produce glycosuria as their primary mechanism of action, by inhibiting sodium/glucose cotransporter...
along with beta blockers, mineralocorticoid receptor antagonists and SGLT2inhibitors are recommended. Diuretics may also be prescribed to prevent fluid...
reproductive system. Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins. In the United States...
illness. Certain medications can also cause elevated ketones, such as SGLT2inhibitors causing euglycemic ketoacidosis. Overdose of salicylates or isoniazid...
Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2inhibitor) used for the treatment of type 2 diabetes mellitus. It was approved for...
Global Information